Thrombophilia References
References
2. U.S. National Library of Medicine: Genetics Home Reference, “Your Guide to Understanding Genetic Conditions: Hereditary Antithrombin Deficiency,” https://ghr.nlm.nih.gov/condition/hereditary-antithrombin-deficiency
3. Heit, J.A.,et. al., “The Epidemiology of Venous Thromboembolism,” J of Thromb Thrombolysis, 2016; 41: 3-14.
4. Centers for Disease Control and Prevention, “Leading Causes of Death,” https://www.cdc.gov/nchs/fastats/leading-causes-of-death
5. Centers for Disease Control and Prevention, “Venous Thromboembolism (Blood Clots): Data and Statistics,” https://www.cdc.gov/ncbddd/dvt/data.html
6. National Blood Clot Alliance, “Hospitalization: A Major Risk Factor for Dangerous Blood Clots,” https://www.stoptheclot.org/spreadtheword/wp-content/uploads/2016/06/Hospitalization-Infographic.pdf
7. Heit, J.A., et. al., “The Epidemiology of Venous Thromboembolism,” J of Thromb Thrombolysis, 2016; 41: 3-14.
8. Bates, S., et. al., “Guidance for the treatment and prevention of obstetric-associated venous thromboembolism,” J Thromb Thrombolysis (2016) 41:92–128
9. Schick, P., Medscape, “Hereditary and Acquired Hypercoagulability Workup: Laboratory Studies,” May 26,2016. https://emedicine.medscape.com/article/211039-workup
10. Connors, J., “Thrombophilia Testing and Venous Thrombosis,” N Engl J Med 2017;377:1177-87.
11. National Blood Clot Alliance, “https://www.stoptheclot.org/antithrombin-deficiency
12. Ornstein, D., “Cardiology Update: Factor V Leiden,” Circulation. 2003;107:e94-e97.
13. Ibid.
14. Ibid.
15. Curtis KM, Tepper NK, Jatlaoui TC, Berry-Bibee E, Horton LG, Zapata LB, Simmons KB, Pagano HP, Jamieson DJ, Whiteman MK, MMWR Recomm Rep. 2016 Jul 29;65(3):1-103. doi: 10.15585/mmwr.rr6503a1. U.S. Medical Eligibility Criteria for Contraceptive Use, 2016.
16. Ornstein, D., “Cardiology Update: Factor V Leiden,” Circulation. 2003;107:e94-e97.
17. Ibid.
18. Patnaik MM, Moll S. Haemophilia. 2008;14(6):1229-1239.; Wells PS, Blajchman MA,
Henderson P, et al. Am J Hematol. 1994;45:321-324.
19. U.S. National Library of Medicine: Genetics Home Reference, “Your Guide to Understanding Genetic Conditions: Hereditary Antithrombin Deficiency,” https://ghr.nlm.nih.gov/condition/hereditary-antithrombin-deficiency
20. The Clinical Adviser, “Antithrombin Deficiency,” http://www.clinicaladvisor.com/labmed/antithrombin-deficiency/article/614356/
21. Varga, E., et.al., “Prothrombin 20210 Mutation (Factor II Mutation),” Circulation 2004;110;e15-e18. http://circ.ahajournals.org/content/110/3/e15
22. Ibid.
23. Miletich, J., et.al., Absence of Thrombosis in Subjects with Heterozygous Protein C Deficiency, New England Journal of Medicine, 1987;317:991-996
24. U.S. National Library of Medicine: Genetics Home Reference, “Your Guide to Understanding Genetic Conditions: Protein C Deficiency,” https://ghr.nlm.nih.gov/condition/protein-c-deficiency#resources
25. U.S. National Library of Medicine: Genetics Home Reference, “Your Guide to Understanding Genetic Conditions: Protein S Deficiency,” https://ghr.nlm.nih.gov/condition/protein-s-deficiency#genes
26. Mandava, P., et. al., “Drugs and Diseases: Homocystinuria/Homocysteinemia,” Medscape, https://emedicine.medscape.com/article/1952251-overview#a3
27. Piazza, G., “Thrombophilia and Hypercoagulability,” Circulation, 2014;130:e9-e10.
28. Connors, J., “Thrombophilia Testing and Venous Thrombosis,” N Engl J Med 2017;377:1177-87.
29. Ansell, J., “Management of venous thromboembolism: clinical guidance from the Anticoagulation Forum,” J Thromb Thrombolysis, 2016:41:1-2.
30. Vedantham, S., “Guidance for the use of thrombolytic therapy for the treatment of venous thromboembolism,” J Thromb Thrombolysis (2016) 41:72.
31. Burnett, A., et. al., “Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment,” J Thromb Thrombolysis, (2016) 41:1.
32. Ibid.
33. Ibid.
34. B Myers, R Neal, O Myers, M Ruparelia, Unplanned pregnancy on a direct oral anticoagulant (Rivaroxaban): A warning, Obstet Med. 2016 Mar; 9(1): 40–42. Published online 2015 Dec 24. doi: 10.1177/1753495X15621814